



ANSWERS FOR CANCER

Genetron Health to Present at Upcoming Investor Conferences

September 8, 2020

BEIJING, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, today announced that its executive management team will participate in the following conferences.

- ICBCI International ADR New Economy Conference from September 15-18, 2020: Management will be available for virtual one on one and group meetings on September 15, 2020.
- SVB Leerink CyberRx Series: Oncology Dx and Liquid Biopsy Summit on October 6, 2020: Management will participate in a virtual video fireside chat on October 6 at 9:00 am ET.

Interested parties may request more information by contacting their sales representatives at ICBCI and SVB Leerink, respectively.

About Genetron Holdings Limited

Genetron Holdings Limited ("Genetron Health" or the "Company") is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contacts

US:

Hoki Luk

Head of Investor Relations

Email: hoki.luk@genetronhealth.com

Phone: +1 (408) 891-9255

Stephanie Carrington

Westwicke, an ICR Company

Email: Stephanie.Carrington@westwicke.com

Phone: +1 (646) 277-1282

Asia:

Bill Zima

ICR, Inc.

Email: bill.zima@icrinc.com

GenetronIR@icrinc.com

Media Relations Contact

Edmond Lococo

ICR

Email: Edmond.Lococo@icrinc.com

Mobile: +86 138-1079-1408

genetron.pr@icrinc.com